ADAM9 and Renal Cell Cancer
Author Information
Author(s): Fritzsche Florian R, Wassermann Kirsten, Jung Monika, Tölle Angelika, Kristiansen Ilka, Lein Michael, Johannsen Manfred, Dietel Manfred, Jung Klaus, Kristiansen Glen
Primary Institution: Charité – Universitätsmedizin Berlin
Hypothesis
The study evaluates the expression of ADAM9 in renal cell carcinoma and its association with tumor progression.
Conclusion
ADAM9 is strongly expressed in a large proportion of renal cell cancers and is significantly associated with markers of unfavorable prognosis.
Supporting Evidence
- ADAM9 mRNA was significantly up-regulated in renal cancer compared to adjacent normal tissue.
- ADAM9 protein expression was associated with higher tumor grade and positive nodal status.
- Patients with high ADAM9 expression had significantly shorter survival times.
Takeaway
ADAM9 is a protein that can help doctors understand how aggressive a kidney cancer is, and higher levels of it might mean a worse outcome for patients.
Methodology
The study involved immunostaining of 108 renal cancer cases and quantitative RT-PCR analysis of ADAM9 mRNA in 30 additional cases.
Limitations
The prognostic value of ADAM9 was not verified in larger study cohorts.
Participant Demographics
The study included 108 patients (83 men, 25 women) with a median age of 62 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website